肝脏 ›› 2026, Vol. 31 ›› Issue (9): 1366-1371.
陈芳芳, 李静, 杨晓娟, 张文杰, 卡毛加, 周宁
收稿日期:2025-11-27
出版日期:2026-09-30
发布日期:2026-11-16
通讯作者:
周宁, Email: zntd19820708@163.com
基金资助:
Received:2025-11-27
Online:2026-09-30
Published:2026-11-16
摘要: 代谢相关脂肪性肝病(MASLD)在全球范围内的流行态势日益严峻,已成为重大的疾病负担。近年来,肠道微生态失衡通过“肠肝轴”驱动MASLD发生和发展的核心作用日益明确,其作用机制涉及菌群代谢产物(如丁酸盐、胆汁酸、氧化三甲胺等)通过调控表观遗传修饰影响肝脏脂质代谢与炎症反应。本文系统梳理了该领域最新进展,重点探讨了肠道菌群在MASLD进展中呈现的时空动态特征(包括菌群演替、昼夜节律与肠段分布差异),以及宿主遗传和饮食地理因素对个体易感性的影响。本文还展望了针对肠道微生态的精准干预策略,如代谢物靶向治疗、时序性干预及工程菌应用等前沿方向,并指出需通过多学科融合以突破临床转化瓶颈,为实现MASLD的个体化防治提供新视角。
陈芳芳, 李静, 杨晓娟, 张文杰, 卡毛加, 周宁. 肠道微生态在代谢相关脂肪性肝病中的调控机制与精准干预研究进展[J]. 肝脏, 2026, 31(9): 1366-1371.
| [1] Younossi Z M, Golabi P, Paik J M, et al. The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review[J]. Hepatology,2023,77(4):1335-1347. [2] Tilg H, Adolph T E, Trauner M. Gut-liver axis: pathophysiological concepts and clinical implications[J]. Cell Metab,2022,34(11):1700-1718. [3] Rong L, Zou J, Ran W,et al. Advancements in the treatment of non-alcoholic fatty liver disease (NAFLD)[J]. Front Endocrinol (Lausanne) ,2023,13:1087260. [4] Zhao Z H, Wang Z X, Zhou D, et al. Sodium butyrate supplementation inhibits hepatic steatosis by stimulating liver kinase B1 and insulin-induced gene[J]. Cell Mol Gastroenterol Hepatol,2021,12(3):857-871. [5] Huang L J, Wang M Y, Xin F Z, et al. Sodium butyrate ameliorates liver fibrosis in metabolic dysfunction-associated steatohepatitis rats via miR-155-5p/SOCS1/PDGF signaling pathway[J]. Hepatobiliary Pancreat Dis Int,2025,24(4):423-432. [6] Li X, Su C, Jiang Z, et al. Berberine attenuates choline-induced atherosclerosis by inhibiting trimethylamine and trimethylamine-N-oxide production via manipulating the gut microbiome[J]. NPJ Biofilms Microbiomes,2021,7(1):36. [7] Ding N, Wang K, Jiang H, et al. AGK regulates the progression to NASH by affecting mitochondria complex I function[J]. Theranostics,2022,12(7):3237-3250. [8] Shi C, Pei M, Wang Y, et al. Changes of flavin-containing monooxygenases and trimethylamine-N-oxide may be involved in the promotion of non-alcoholic fatty liver disease by intestinal microbiota metabolite trimethylamine[J]. Biochem Biophys Res Commun,2022,594:1-7. [9] Cao Y N, Yue S S, Wang A Y, et al. Antrodia cinnamomea and its compound dehydroeburicoic acid attenuate nonalcoholic fatty liver disease by upregulating ALDH2 activity[J]. J Ethnopharmacol,2022,292:115146. [10] Li F, Jiang C, Krausz K W, et al. Microbiome remodelling leads to inhibition of intestinal farnesoid X receptor signalling and decreased obesity[J]. Nat Commun,2013,4:2384. [11] Fiorucci S, Distrutti E. The pharmacology of bile acids and their receptors[J]. Handb Exp Pharmacol,2019,256:3-18. [12] Yang Z H, Liu F, Zhu X R, et al. Altered profiles of fecal bile acids correlate with gut microbiota and inflammatory responses in patients with ulcerative colitis[J]. World J Gastroenterol,2021,27(24):3609-3629. [13] Sun Y, Zhu M, Zhao H, et al. Serum fibroblast growth factor 19 and total bile acid concentrations are potential biomarkers of hepatocellular carcinoma in patients with type 2 diabetes mellitus[J]. Biomed Res Int,2020,2020:1751989. [14] Min B H, Devi S, Kwon G H, et al. Gut microbiota-derived indole compounds attenuate metabolic dysfunction-associated steatotic liver disease by improving fat metabolism and inflammation[J].Gut Microbes,2024,16(1):2307568. [15] 张浩原,赵真旺,张敏. 3-吲哚丙酸在代谢性疾病中的研究进展[J].中国病理生理杂志,2024, 40(10): 1957-1962. [16] Li J, Chen X, Song S, et al. Hexokinase 2-mediated metabolic stress and inflammation burden of liver macrophages via histone lactylation in MASLD[J]. Cell Rep,2025,44(3):115350. [17] Tan X, Liu Y, Long J, et al. Trimethylamine N-oxide aggravates liver steatosis through modulation of bile acid metabolism and inhibition of farnesoid X receptor signaling in nonalcoholic fatty liver disease[J]. Mol Nutr Food Res,2019,63(17):e1900257. [18] Zhao M, Zhao J, Yang H, et al. The bile acid-gut microbiota axis: a central hub for physiological regulation and a novel therapeutic target for metabolic diseases[J].Biomed Pharmacother,2025,188:118182. [19] Schnabl B, Damman C J, Carr R M. Metabolic dysfunction-associated steatotic liver disease and the gut microbiome: pathogenic insights and therapeutic innovations[J].J Clin Invest,2025,135(7):e186423. [20] Lau H C, Zhang X, Yu J. Gut microbiome in metabolic dysfunction-associated steatotic liver disease and associated hepatocellular carcinoma[J].Nat Rev Gastroenterol Hepatol, 2025,22(9):619-638. [21] Wang L, Wang H, Wu J, et al. Gut microbiota and metabolomics in metabolic dysfunction-associated fatty liver disease: interaction, mechanism, and therapeutic value[J].Front Cell Infect Microbiol,2025,15:1635638. [22] Wang L J, Sun J G, Chen S C, et al. The role of intestinal flora in metabolic dysfunction-associated steatotic liver disease and treatment strategies[J].Front Med (Lausanne),2025,11:1490929. [23] Leone V, Gibbons S M, Martinez K, et al. Effects of diurnal variation of gut microbes and high-fat feeding on host circadian clock function and metabolism[J].Cell Host Microbe,2015,17(5):681-689. [24] Gutierrez Lopez D E, Lashinger L M, Weinstock G M, et al. Circadian rhythms and the gut microbiome synchronize the host's metabolic response to diet[J].Cell Metab,2021,33(5):873-887. [25] Ramos S F, Siguenza N, Zhong W, et al. Metatranscriptomics uncover diurnal functional shifts in bacterial transgenes with profound metabolic effects[J].Cell Host Microbe,2025,33(7):1057-1072. [26] Saran A R, Dave S, Zarrinpar A. Circadian rhythms in the pathogenesis and treatment of fatty liver disease[J].Gastroenterology,2020,158(7):1948-1966.e1. [27] Sundin O H, Mendoza-Ladd A, Zeng M, et al. The human jejunum has an endogenous microbiota that differs from those in the oral cavity and colon[J].BMC Microbiol,2017,17(1):160. [28] Yuan C, Graham M, Staley C, et al. Mucosal microbiota and metabolome along the intestinal tract reveal a location-specific relationship[J].mSystems,2020,5(3):e00055-20. [29] Lkhagva E, Chung H J, Hong J, et al. The regional diversity of gut microbiome along the GI tract of male C57BL/6 mice[J].BMC Microbiol,2021,21(1):44. [30] Huang Z, Boekhorst J, Fogliano V, et al. Distinct effects of fiber and colon segment on microbiota-derived indoles and short-chain fatty acids[J].Food Chem,2023,398:133801. [31] 程薏霏,刘金波,陈丽.代谢功能障碍相关脂肪性肝病的风险因素和发病机制[J].临床内科杂志,2025,42(5):356-360. [32] Sun B, Ding X, Tan J, et al.TM6SF2 E167K variant decreases PNPLA3-mediated PUFA transfer to promote hepatic steatosis and injury in MASLD[J].Clin Mol Hepatol,2024 ,30(4):863-882. [33] Chen L Z, Wang Y R, Zhao Z Z, et al. Intestinal depletion of TM6SF2 exacerbates high-fat diet-induced metabolic dysfunction-associated steatotic liver disease through the gut-liver axis[J].J Clin Transl Hepatol,2025,13(6):443-455. [34] Albenberg L G, Wu G D. Diet and the intestinal microbiome: associations,functions, and implications for health and disease[J].Gastroenterology,2014,146(6):1564-1572. [35] Zhang J, Qi H, Li M, et al. Diet mediate the impact of host habitat on gut microbiome and influence clinical indexes by modulating gut microbes and serum metabolites[J].Adv Sci (Weinh),2024,11(19):e2310068. [36] He Y, Wu W, Zheng H M, et al. Regional variation limits applications of healthy gut microbiome reference ranges and disease models[J].Nat Med,2018,24(10):1532-1535. [37] Lu J, Zhang L, Zhai Q,et al. Chinese gut microbiota and its associations with staple food type, ethnicity, and urbanization[J].NPJ Biofilms Microbiomes,2021,7(1):71. [38] Gaundal L, Myhrstad M C W, Rud I, et al. Gut microbiota is associated with dietary intake and metabolic markers in healthy individuals[J].Food Nutr Res,2022,23:66. [39] Kim H, Nelson P, Nzabarushimana E, et al. Multi-omic analysis reveals transkingdom gut dysbiosis in metabolic dysfunction-associated steatotic liver disease[J].Nat Metab,2025,7(7):1476-1492. [40] Zhou S, Li M, Wang P, et al. A symbiotic filamentous gut fungus ameliorates MASH via a secondary metabolite-CerS6-ceramide axis[J].Science,2025,388(6746):eadp5540. [41] Hickey E, Leaves I, Pradhan A,et al. Effects of short-chain fatty acid combinations relevant to the healthy and dysbiotic gut upon candida albicans[J].Curr Microbiol,2025,82(9):420. [42] Weinberger V, Mohammadzadeh R, Blohs M, et al. Expanding the cultivable humanarchaeome: methanobrevibacter intestini sp. nov. and strain Methanobrevibacter smithii 'GRAZ-2' from human faeces[J].Int J Syst Evol Microbiol,2025,75(4):006751. [43] Zhang S, Zhao J, Xie F, et al. Dietary fiber-derived short-chain fatty acids: a potential therapeutic target to alleviate obesity-related nonalcoholic fatty liver disease[J].Obes Rev,2021,22(11):e13316. [44] Ni Y, Qian L, Siliceo S L, et al. Resistant starch decreases intrahepatic triglycerides in patients with NAFLD via gut microbiome alterations[J].Cell Metab,2023,35(9):1530-1547.e8. [45] Wang S L, Liang S, Li S Y, et al. Lactobacillus rhamnosus GG attenuates MASLD/MASH progression by modulating gut microbiota and metabolic pathways[J].Front Microbiol, 2025,16:1586678. [46] Alonso-Allende J, Milagro F I, Aranaz P. Health effects and mechanisms of inulin action in human metabolism[J].Nutrients,2024,16(17):2935. [47] Groenewegen B, Ruissen M M, Crossette E, et al. Consecutive fecal microbiota transplantation for metabolic dysfunction-associated steatotic liver disease: a randomized controlled trial[J].Gut Microbes,2025,17(1):2541035. [48] Nie Q, Luo X, Wang K, et al. Gut symbionts alleviate MASH through a secondary bile acid biosynthetic pathway[J].Cell,2024,187(11):2717-2734.e33. [49] Wu N, Ma Y C, Gong X Q, et al. The metabolite alpha-ketobutyrate extends life span by promoting peroxisomal function in C. elegans[J].Nat Commun,2023,14(1):240. [50] Zhang Y, Wang X, Lin J, et al. A microbial metabolite inhibits the HIF-2α-ceramide pathway to mediate the beneficial effects of time-restricted feeding on MASH[J].Cell Metab,2024,36(8):1823-1838.e6. [51] Luo X, Wang K, Jiang C. Gut microbial enzymes and metabolic dysfunction-associated steatohepatitis: function, mechanism, and therapeutic prospects[J].Cell Host Microbe, 2025,33(6):836-853. [52] Moon J S, Hong J H, Jung Y J, et al. SGLT-2 inhibitors and GLP-1 receptor agonistsin metabolic dysfunction-associated fatty liver disease[J].Trends Endocrinol Metab,2022,33(6):424-442. [53] Ji L, Gao L, Xue H,et al. Efficacy and safety of a biased GLP-1 receptor agonist ecnoglutide in adults with overweight or obesity: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial[J].Lancet Diabetes Endocrinol,2025,13(9):777-789. [54] Jiang J, Gao Y, Wang J,et al. Hepatic sphingomyelin phosphodiesterase 3 promotes steatohepatitis by disrupting membrane sphingolipid metabolism[J].Cell Metab,2025,37(5):1119-1136.e13. [55] Yang W, Jin Q, Xiao D,et al. Interaction mechanism and intervention strategy between metabolic dysfunction-associated steatotic liver disease and intestinal microbiota[J].Front Microbiol,2025,16:1597995. |
| [1] | 薛俊杰, 陈楠, 陈萌萌, 奉镭. 肠肝轴在肝硬化中的作用机制及靶向治疗新策略[J]. 肝脏, 2026, 31(9): 1371-1375. |
| [2] | 孙悦, 牛昊书. 基于16S rDNA测序对比分析酒精性脂肪肝和代谢相关脂肪性肝病患者的肠道微生物特征[J]. 肝脏, 2026, 31(8): 1146-1151. |
| [3] | 李俊缨, 陈金军. 代谢功能障碍相关脂肪性肝病高危人群的监测及管理[J]. 肝脏, 2026, 31(8): 1192-1195. |
| [4] | 徐璐, 芮法娟, 胡新玉, 李婕. 代谢相关脂肪性肝病进展综合防控策略[J]. 肝脏, 2026, 31(6): 778-786. |
| [5] | 何新龙, 范建高, 杨蕊旭. 蛋白质组学在代谢相关脂肪性肝病精准诊疗中的研究进展与挑战[J]. 肝脏, 2026, 31(6): 786-789. |
| [6] | 赵英超, 罗朵朵, 武湘华, 任育慧, 王艳, 强晓辉, 杜海峰. 剪切波弹性成像联合APRI诊断酒精性肝病患者肝纤维化程度的价值[J]. 肝脏, 2026, 31(6): 847-850. |
| [7] | 许城英, 孙璐, 毛成洁, 王敏英, 陆忠华. 血清Ⅳ型胶原相对值及其组合模型在代谢相关脂肪性肝病肝脏炎症与纤维化评估中的应用价值[J]. 肝脏, 2026, 31(6): 886-890. |
| [8] | 王晓明, 郭甜甜, 常柳祎, 罗娟, 王宇, 欧晓娟, 贾继东, 赵新颜. 血清抗核抗体滴度与代谢相关脂肪性肝病临床病理特征的相关性研究[J]. 肝脏, 2026, 31(5): 668-672. |
| [9] | 刘晓桐, 张保静, 王满, 吴凤霞, 宋晨源, 王树俊. ZJU指数、TyG指数及其衍生指数在代谢相关脂肪性肝病筛查及严重程度预测中的价值[J]. 肝脏, 2026, 31(5): 697-703. |
| [10] | 孟祥英, 叶威巍, 夏芳, 樊民, 刘浩琪, 王奕, 赵倩. 中医适宜技术干预代谢相关脂肪性肝病的研究进展[J]. 肝脏, 2026, 31(5): 751-754. |
| [11] | 张月霞, 王宇, 冯艳苹, 高岩. 不同人体测量指标对代谢相关脂肪性肝病诊断价值的比较[J]. 肝脏, 2026, 31(1): 75-80. |
| [12] | 常柳祎, 邵茉莉, 滕国鑫, 马子坤, 李敏, 赵新颜. 代谢相关脂肪性肝病进展期肝纤维化的临床病理特征及预后分析[J]. 肝脏, 2025, 30(9): 1186-1191. |
| [13] | 冯巩, 李如欣, 党焓悦, 李文彤, 弥曼, 陈敏, 严琴琴. 儿童代谢相关性脂肪肝的无创诊断研究进展[J]. 肝脏, 2025, 30(9): 1292-1295. |
| [14] | 张粉娜, 张心怡, 吕贝贝, 孙荣荣, 赵婷婷, 贺娜. NAFLD到MAFLD/MASLD学术更名后流行病学和诊疗结局的变化[J]. 肝脏, 2025, 30(7): 900-903. |
| [15] | 刘爱芳, 罗磊, 杨文龙. 国内外代谢相关脂肪性肝病管理指南中生活方式干预对比[J]. 肝脏, 2025, 30(7): 1012-1016. |
| 阅读次数 | ||||||
|
全文 |
|
|||||
|
摘要 |
|
|||||